Sm934 treated lupus-prone NZB×NZW F 1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Hou, Li Fei ^a   He, Shi Jun ^a   Li, Xin ^a   Wan, Chun Ping ^b   Yang, Yang ^b   Zhang, Xiao Hui ^b   He, Pei Lan ^a   Zhou, Yu ^a   Zhu, Feng Hua ^a   Yang, Yi Fu ^b   Li, Ying ^a   Tang, Wei ^a   Zuo, Jian Ping ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ DERIVATIVE; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; PREDNISOLONE; SM 934; UNCLASSIFIED DRUG; BETA AMINOARTEETHER MALEATE; BETA-AMINOARTEETHER MALEATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ANIMAL; GLOMERULONEPHRITIS; HELPER CELL; IMMUNOLOGY; METABOLISM; ORAL DRUG ADMINISTRATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

MUS;

ADMINISTRATION, ORAL; ANIMALS; ARTEMISININS; FEMALE; GLOMERULONEPHRITIS; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84863288447     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032424     Document Type: Article

References (49)

1. Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC, (2010) T cells as therapeutic targets in SLE. Nat Rev Rheumatol 6: 317-325.
2. Sanz I, Lee FE-H, (2010) B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6: 326-337.
3. Brian LK, (1996) Systemic Lupus Erythematosus. Cell 85: 303-306.
4. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, et al. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148: 1198-1215.
5. Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, et al. (1999) Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 42: 1644-1648.
6. Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, et al. (2001) Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 44: 2097-2106.
7. Peng SL, Moslehi J, Craft J, (1997) Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 99: 1936-1946.
8. Haas C, Ryffel B, Le Hir M, (1998) IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB×NZW)F1 mice. J Immunol 160: 3713-3718.
9. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, et al. (2005) Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 175: 8392-8400.
10. Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI, (2006) Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 177: 1451-1459.
11. Humrich JY, Morbach H, Undeutsch R, Enghard P, Rosenberger S, et al. (2010) Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A 107: 204-209.
12. Miossec P, Korn T, Kuchroo VK, (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361: 888-898.
13. Zhou L, Chong MM, Littman DR, (2009) Plasticity of CD4+ T cell lineage differentiation. Immunity 30: 646-655.
14. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL, (2008) gammadelta T cells: an important source of IL-17. Curr Opin Immunol 20: 353-357.
15. Cua DJ, Tato CM, (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10: 479-489.
16. Feng T, Qin H, Wang L, Benveniste EN, Elson CO, et al. (2011) Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J Immunol 186: 6313-6318.
17. He D, Wu L, Kim HK, Li H, Elmets CA, et al. (2009) IL-17 and IFN-gamma mediate the elicitation of contact hypersensitivity responses by different mechanisms and both are required for optimal responses. J Immunol 183: 1463-1470.
18. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, et al. (2002) Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17: 375-387.
19. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, et al. (2009) Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799-810.
20. Crispin JC, Tsokos GC, (2010) Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol 22: 499-503.
21. Garrett-Sinha LA, John S, Gaffen SL, (2008) IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 20: 519-525.
22. Llorente L, Richaud-Patin Y, (2003) The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun 20: 287-289.
23. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, et al. (1995) Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4: 393-395.
24. Park YB, Lee SK, Kim DS, Lee J, Lee CH, et al. (1998) Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16: 283-288.
25. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, et al. (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43: 1790-1800.
26. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, et al. (1994) Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179: 305-310.
27. Yin Z, Bahtiyar G, Zhang N, Liu L, Zhu P, et al. (2002) IL-10 regulates murine lupus. J Immunol 169: 2148-2155.
28. Blenman KR, Duan B, Xu Z, Wan S, Atkinson MA, et al. (2006) IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest 86: 1136-1148.
29. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A, (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
30. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, et al. (2009) Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10: 1178-1184.
31. Lu L, (2002) [Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 22: 169-171.
32. Wang JX, Tang W, Shi LP, Wan J, Zhou R, et al. (2007) Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol 150: 652-661.
33. Wang JX, Tang W, Zhou R, Wan J, Shi LP, et al. (2008) The new water-soluble artemisinin derivative SM905 ameliorates collagen-induced arthritis by suppression of inflammatory and Th17 responses. Br J Pharmacol 153: 1303-1310.
34. Hou LF, He SJ, Wang JX, Yang Y, Zhu FH, et al. (2009) SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol 9: 1509-1517.
35. Wang JX, Hou LF, Yang Y, Tang W, Li Y, et al. (2009) SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages. Acta Pharmacol Sin 30: 1428-1435.
36. Jin O, Zhang H, Gu Z, Zhao S, Xu T, et al. (2009) A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol 6: 461-467.
37. Wu X, Zhang W, Shi X, An P, Sun W, et al. (2010) Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. Acta Biochim Biophys Sin (Shanghai) 42: 916-923.
38. Hou LF, He SJ, Li X, Yang Y, He PL, et al. (2011) Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum 63: 2445-2455.
39. Reilly CM, Gilkeson GS, (2002) Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunol Res 25: 143-153.
40. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV, (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203: 789-797.
41. Boross P, Arandhara VL, Martin-Ramirez J, Santiago-Raber ML, Carlucci F, et al. (2011) The inhibiting Fc receptor for IgG, Fcgamma RIIB, is a modifier of autoimmune susceptibility. J Immunol 187: 1304-1313.
42. Renno T, Attinger A, Rimoldi D, Hahne M, Tschopp J, et al. (1998) Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol 28: 540-547.
43. Renno T, Hahne M, Tschopp J, MacDonald HR, (1996) Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med 183: 431-437.
44. Hughes GC, Martin D, Zhang K, Hudkins KL, Alpers CE, et al. (2009) Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice. Arthritis Rheum 60: 1775-1784.
45. Monk CR, Spachidou M, Rovis F, Leung E, Botto M, et al. (2005) MRL/Mp CD4+,CD25- T cells show reduced sensitivity to suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum 52: 1180-1184.
46. Wang L, Tassiulas I, Park-Min KH, Reid AC, Gil-Henn H, et al. (2008) 'Tuning' of type I interferon-induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages. Nat Immunol 9: 186-193.
47. Gergely P Jr, Niland B, Gonchoroff N, Pullmann R Jr, Phillips PE, et al. (2002) Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol 169: 1092-1101.
48. Yuan W, DiMartino SJ, Redecha PB, Ivashkiv LB, Salmon JE, (2011) Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes. Arthritis Rheum 63: 212-218.
49. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, et al. (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.